Advisors Preferred LLC Trims Stock Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Advisors Preferred LLC lessened its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 47.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,372 shares of the company’s stock after selling 2,183 shares during the period. Advisors Preferred LLC’s holdings in Centessa Pharmaceuticals were worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in CNTA. The Manufacturers Life Insurance Company raised its holdings in shares of Centessa Pharmaceuticals by 30.4% during the second quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company’s stock worth $1,272,000 after purchasing an additional 32,846 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Harbour Capital Advisors LLC purchased a new position in shares of Centessa Pharmaceuticals during the third quarter worth $259,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after purchasing an additional 6,785 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 6.7 %

Shares of NASDAQ CNTA opened at $19.03 on Friday. The company’s 50-day simple moving average is $16.77 and its 200-day simple moving average is $15.40. Centessa Pharmaceuticals plc has a 52-week low of $7.38 and a 52-week high of $19.09. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the topic of several analyst reports. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim raised their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $25.83.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Saurabh Saha sold 1,671 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the completion of the transaction, the chief executive officer now directly owns 575,661 shares in the company, valued at approximately $10,500,056.64. This represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 421,697 shares of company stock worth $7,211,475 over the last 90 days. 11.59% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.